ArticleFrontiers in psychiatry2023
Group psychedelic therapy: empirical estimates of cost-savings and improved access.
Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07737990 (Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer.BMC medicine · 2026Article
- Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.Psychopharmacology · 2026Review
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Molecular psychiatry · 2026Review
- Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026Review
- Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.Psychedelic medicine (New Rochelle, N.Y.) · 2026Article
- Not a Standalone Treatment: Considerations for Psychedelic-Assisted Therapy.Brain and behavior · 2026Review
- Priorities for public health preparedness for psychedelics: education, workforce readiness, and strategic information needs in a rapidly changing landscape.Frontiers in public health · 2026Article
- Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico.Frontiers in public health · 2026Article
- A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience.Frontiers in public health · 2026Article
- Systems-based psychiatry: insights from psychedelic research on mechanisms of healing.Frontiers in psychiatry · 2026Article
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry.Journal of personalized medicine · 2025Review
- Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.Translational psychiatry · 2025Article
- Investing in Group Psychedelic Therapy for Latinx Immigrants.Journal of immigrant and minority health · 2025Article
- The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress.Healthcare (Basel, Switzerland) · 2025Article
- Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.Therapeutic advances in psychopharmacology · 2025Review
- Ketamine-assisted group psychotherapy integrating cognitive processing therapy to address identity-based trauma: a pilot study.Frontiers in psychiatry · 2025Article
- Psychedelics and the treatment of eating disorders: considerations for future research and practice.Journal of eating disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods: Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician costs and clinician time required by therapy protocols utilizing groups versus individual patient therapy. Using published literature, we estimated the prevalence of adults with PTSD and MDD eligible for treatment with psychedelic therapy and projected the savings in time and cost required to treat these prevalent cases. Results: Group therapy saved 50.9% of clinician costs for MDMA-PTSD and 34.7% for psilocybin-MDD, or $3,467 and $981 per patient, respectively. To treat all eligible PTSD and MDD patients in the U.S. in 10 years with group therapy, 6,711 fewer full-time equivalent (FTE) clinicians for MDMA-PTSD and 1,159 fewer for FTE clinicians for psilocybin-MDD would be needed, saving up to $10.3 billion and $2.0 billion respectively, discounted at 3% annually. Conclusion: Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies. By enhancing the number of patients served per clinician, group therapy could also ameliorate the anticipated shortage of appropriately trained clinicians, thereby accelerating access to these promising new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.